In one dataset (cohort 2; GSE10358, which included 304 AML patients, of which 188 AML patients were diagnosed with de novo AML, and exhibited somatic mutations in FLT3, KIT, and JAK2 tyrosine kinase, analysed by high-throughput re-sequencing), increased levels of M2-like Mφs correlated with inferior OS and event-free survival in AML patients, which they validated by xCell analysis. Here, KIT is linked to acute myeloid leukemia.